ZYME

Zymeworks Inc. [ZYME] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ZYME Stock Summary

In the News

ZYME Financial details

Company Rating
-
Market Cap
652.76M
Income
-118.67M
Revenue
76.01M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
272
Optionable
No
Shortable
Yes
Earnings
02 Aug 2023
P/E
3.95
Forward P/E
-
PEG
-0.22
P/S
1.74
P/B
1.91
P/C
-
P/FCF
4.19
Quick Ratio
4.98
Current Ratio
5.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.53
EPS next Y
-
EPS next Q
-
EPS this Y
-190.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-14.79%
Revenue last 5Y
20.8%
Revenue Q/Q
2.54%
EPS Q/Q
-
-
-
-
-
SMA20
-7.68%
SMA50
3.77%
SMA100
0.98%
Inst Own
-
Inst Trans
-
ROA
37%
ROE
45%
ROC
0.42%
Gross Margin
100%
Oper. Margin
44%
Profit Margin
44%
Payout
1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.015-13.14
52W High
+84.92%
52W Low
+300.67%
RSI
42.21
Rel Volume
0.84
Avg Volume
554.23K
Volume
464.86K
Perf Week
-3.03%
Perf Month
-12.36%
Perf Quarter
-3.61%
Perf Half Y
-9.93%
-
-
-
-
Beta
1.111
-
-
Volatility
0.52%, 1.47%
Prev Close
-4.22%
Price
24.04
Change
-2.44%

Something similar

Top by Market Cap
META
VOO
LLY
APC.DE
GOOG
Same Sector
ALC.SW
600436.SS
IGMS
ENTX
601607.SS
Same Price Range
NDBKY
3550.TW
0551.HK
XAAG.DE
SBSI
Similar Market Cap
CSII
PCTTW
TCS.TO
THL.NZ
ETLS.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 554.23K
  • Market Capitalization 652.76M
  • Employee 272
  • CEO Mr. Kenneth H. Galbraith C.A.
  • Headquarters Vancouver,BC,CA
  • IPO Date 2017-04-28
  • Website https://www.zymeworks.com

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.